Oncology experts roundtable: Practical insights on FDA draft guidance discussing OS data in cancer trials
This round table discussion is part of The Regulatory Navigator series, where we explore the evolving regulatory landscape with actionable insight from Parexel's experts, sharing their experience to maximize success for clinical development and patient access.
Hosted by former EMA regulator Sinan B. Sarac, M.D., Ph.D., SVP Head of Oncology Europe at Parexel, this roundtable discusses the recently published FDA draft guidance "Approaches to Assessment of Overall Survival in Oncology Clinical Trials.” Sinan is joined by Bernardo Haddock Lobo Goulart, M.D., VP Parexel Regulatory Consulting and former FDA regulator, and Aaron Sosa, M.D., VP Parexel Regulatory Consulting and former EMA regulator.
The FDA's new draft guidance establishes overall survival (OS) as both an efficacy and safety endpoint in oncology trials, requiring its assessment even when not the primary endpoint. Parexel's oncology experts emphasize that sponsors must pre-specify OS analysis in statistical plans with clear harm thresholds to ensure surrogate endpoints don't mask potential harm. Both FDA and EMA are aligned in this approach, recognizing that while OS may not always be feasible as a primary endpoint, it remains central to regulatory evaluation and benefit-risk assessment.
Related Insights
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Related Insights
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023